Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Timing of Radiotherapy with Chemoimmunotherapy in Advanced ESCC
ChiCTR2600121693Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 cohorts), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Started Apr 2026; status: recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600121693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121693.